The effect of calcimimetics on complications of chronic kidney disease
Not Applicable
- Conditions
- Chronic kidney disease(CKD)
- Registration Number
- JPRN-UMIN000035414
- Lead Sponsor
- Saitama Tsukinomori Clinic
- Brief Summary
Etelcalcetide was administered to 32 hemodialysis patients with secondary hyperparathyroidism. iPTH, BAP, Osteocalcin, TRACP 5b, and FGF23 decreased significantly, and this decrease persisted.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method